Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29767633 | 0.82 | RXRA (0.34) | RXRARXRBKIF11RXRG | |
| SCHEMBL29773672 | 0.82 | RXRA (0.34) | RXRARXRBKIF11RXRG | |
| SCHEMBL17386730 | 0.82 | RXRA (0.34) | RXRARXRBKIF11RXRG | |
| SCHEMBL28428131 | 0.82 | RXRA (0.32) | RXRARXRBCNR1 | |
| Hydrochloric Acid SCHEMBL28041356 | 0.81 | RXRA (0.33) | RXRARXRBKIF11 | |
| Hydrochloric Acid SCHEMBL29773667 | 0.81 | RXRA (0.33) | RXRARXRBKIF11 | |
| SCHEMBL5859090 | 0.80 | BRD4 (0.33) | — | |
| SCHEMBL18124398 | 0.80 | RXRA (0.33) | RXRARXRB | |
| SCHEMBL5860021 | 0.79 | RXRA (0.31) | RXRARXRB | |
| SCHEMBL17415165 | 0.78 | RXRA (0.31) | RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7081543-B2 | Bridged biscyclopentadienyl ligands and method of preparation | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-07-25 | — | — | US | claimed |
| US-20050250956-A1 | Bridged biscyclopentadienyl ligands and method of preparation | RIX FRANCIS C | 2005-11-10 | — | — | US | claimed |
| US-6960676-B2 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-11-01 | — | — | US | claimed |
| EP-1263764-B1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEM PATENTS INC (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030220190-A1 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2003-11-27 | — | — | US | claimed |
| EP-1263764-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | ExxonMobil Chemical Patents Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| WO-2001058913-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2001-08-16 | — | — | WO | claimed |
| US-7081543-B2 | Bridged biscyclopentadienyl ligands and method of preparation | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20050250956-A1 | Bridged biscyclopentadienyl ligands and method of preparation | RIX FRANCIS C | 2005-11-10 | — | — | US | disclosed |
| US-6960676-B2 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1263764-B1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEM PATENTS INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030220190-A1 | Method of preparing group 14 bridged biscyclopentadienyl ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1263764-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | ExxonMobil Chemical Patents Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001058913-A1 | METHOD OF PREPARING GROUP 14 BRIDGED BISCYCLOPENTADIENYL LIGANDS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250956-A1 | Bridged biscyclopentadienyl ligands and method of preparation | FDPS, PPIP5K2, DBF4 | RXRA 3921/4885RXRB 3927/4885KIF11 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.